ABMD Abiomed Inc

Price (delayed)

$293.77

Market cap

$13.36B

P/E Ratio

61.46

Dividend/share

N/A

EPS

$4.78

Enterprise value

$13.17B

Abiomed is a publicly-traded medical devices company that develops and manufactures the circulatory support device Impella, the world’s smallest heart pump. The company is headquartered in Danvers, Massachusetts and has ...

Highlights
ABMD's EPS has surged by 59% since the previous quarter and by 40% year-on-year
The net income has soared by 59% from the previous quarter and by 41% YoY

Key stats

What are the main financial stats of ABMD
Market
Shares outstanding
45.46M
Market cap
$13.36B
Enterprise value
$13.17B
Valuations
Price to earnings (P/E)
61.46
Price to book (P/B)
8.71
Price to sales (P/S)
12.67
EV/EBIT
48.84
EV/EBITDA
44.28
EV/Sales
12.47
Earnings
Revenue
$1.06B
EBIT
$269.73M
EBITDA
$297.53M
Free cash flow
$262.76M
Per share
EPS
$4.78
Free cash flow per share
$5.77
Book value per share
$33.72
Revenue per share
$23.18
TBVPS
$34.9
Balance sheet
Total assets
$1.7B
Total liabilities
$167.44M
Debt
$0
Equity
$1.54B
Working capital
$919.6M
Liquidity
Debt to equity
0
Current ratio
7.53
Quick ratio
6.65
Net debt/EBITDA
-0.61
Margins
EBITDA margin
28.2%
Gross margin
81.5%
Net margin
20.6%
Operating margin
24.2%
Efficiency
Return on assets
13.4%
Return on equity
14.9%
Return on invested capital
22.4%
Return on capital employed
17.3%
Return on sales
25.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ABMD stock price

How has the Abiomed stock price performed over time
Intraday
0.78%
1 week
0.64%
1 month
10.03%
1 year
-15.07%
YTD
-18.21%
QTD
18.69%

Financial performance

How have Abiomed's revenue and profit performed over time
Revenue
$1.06B
Gross profit
$860.72M
Operating income
$256.06M
Net income
$217.58M
Gross margin
81.5%
Net margin
20.6%
The company's operating income has surged by 82% QoQ and by 75% YoY
Abiomed's operating margin has surged by 78% QoQ and by 55% YoY
The net income has soared by 59% from the previous quarter and by 41% YoY
ABMD's net margin has surged by 56% since the previous quarter and by 25% year-on-year

Growth

What is Abiomed's growth rate over time

Valuation

What is Abiomed stock price valuation
P/E
61.46
P/B
8.71
P/S
12.67
EV/EBIT
48.84
EV/EBITDA
44.28
EV/Sales
12.47
ABMD's EPS has surged by 59% since the previous quarter and by 40% year-on-year
ABMD's P/E is 36% below its last 4 quarters average of 95.9 and 19% below its 5-year quarterly average of 75.1
ABMD's P/B is 31% below its 5-year quarterly average of 12.6 and 13% below its last 4 quarters average of 9.9
Abiomed's equity has increased by 17% YoY and by 2.2% from the previous quarter
The price to sales (P/S) is 22% lower than the 5-year quarterly average of 16.2 and 11% lower than the last 4 quarters average of 14.2
The company's revenue rose by 13% YoY and by 2.4% QoQ

Efficiency

How efficient is Abiomed business performance
ABMD's return on equity has surged by 54% since the previous quarter and by 22% year-on-year
Abiomed's ROA has soared by 54% from the previous quarter and by 24% YoY
ABMD's return on sales is up by 38% since the previous quarter and by 9% year-on-year
The ROIC has grown by 35% from the previous quarter and by 3.2% YoY

Dividends

What is ABMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABMD.

Financial health

How did Abiomed financials performed over time
ABMD's quick ratio is up by 23% year-on-year and by 8% since the previous quarter
Abiomed's current ratio has increased by 17% YoY and by 7% from the previous quarter
ABMD's debt is 100% smaller than its equity
Abiomed's equity has increased by 17% YoY and by 2.2% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.